Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 39
- Registration Number
- NCT01830985
- Locations
- 🇿🇦
Vertex Investigational Site, Stellenbosch, South Africa
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 559
- Registration Number
- NCT01807923
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 563
- Registration Number
- NCT01807949
A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 80
- Registration Number
- NCT01768663
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 43
- Registration Number
- NCT01754935
- Locations
- 🇿🇦
Vertex Investigational Site, Stellenbosch, South Africa
A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT01726946
- Locations
- 🇺🇸
Florida, Orlando, Florida, United States
🇺🇸Texas, Houston, Texas, United States
🇺🇸Tennessee, Germantown, Tennessee, United States
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 125
- Registration Number
- NCT01707290
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 35
- Registration Number
- NCT01705145
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT01701063
Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT01685801
© Copyright 2024. All Rights Reserved by MedPath